Bipolar Disorder: Symptoms, Causes, and Treatment Options

Bipolar disorder is a chronic, treatable mental health condition defined by recurrent shifts between elevated mood states (mania or hypomania) and depressive episodes. These shifts are not the ordinary ups and downs of mood; they are sustained, biologically driven episodes lasting days to weeks that change how a person sleeps, thinks, behaves, and functions. Between episodes, many people experience periods of stable mood, and with evidence-based treatment most achieve meaningful, durable improvement.

The DSM-5-TR groups bipolar disorder into three principal forms — Bipolar I, Bipolar II, and cyclothymic disorder — separated by the severity, duration, and combination of mood episodes a person has experienced. All three sit on a spectrum, share a strong genetic basis, and respond to a combined treatment approach that pairs mood-stabilizing medication with structured psychotherapy.

~2.8%

Source: National Institute of Mental Health (NIMH)

What Is Bipolar Disorder?

Bipolar disorder is a recurrent mood disorder characterized by discrete episodes of abnormal mood elevation (mania or hypomania) and, in most cases, episodes of major depression. It is classified in the DSM-5-TR under "Bipolar and Related Disorders" and assigned ICD-10 code F31 (with subcodes for current episode type and severity). The condition typically emerges in late adolescence or early adulthood — average age of onset is around 25 — and follows a chronic, episodic course across the lifespan.

The defining clinical feature is the manic or hypomanic episode. Without at least one such episode in a person's history, the diagnosis is not bipolar disorder; it is unipolar depression or another mood condition. This distinction matters because antidepressants given alone to someone with undiagnosed bipolar disorder can trigger mania, accelerate cycling, or destabilize mood — one of the most common avoidable harms in mental health care.

Featured definition

Bipolar disorder is a chronic mental health condition involving recurrent episodes of mania or hypomania alternating with episodes of major depression. It is diagnosed using DSM-5-TR criteria, classified as ICD-10 F31, and treated with a combination of mood-stabilizing medication (such as lithium, valproate, lamotrigine, or atypical antipsychotics) and evidence-based psychotherapy (such as CBT, IPSRT, family-focused therapy, or psychoeducation).

The Three Main Types of Bipolar Disorder

DSM-5-TR recognizes three principal forms of bipolar disorder, plus several specifier categories (mixed features, rapid cycling, with psychotic features, with seasonal pattern, peripartum onset). The three principal forms differ in the highest level of mood elevation a person has experienced and in the pattern of depression.

Bipolar I disorder

Bipolar I is defined by at least one lifetime manic episode — a distinct period of abnormally and persistently elevated, expansive, or irritable mood with increased goal-directed activity or energy, lasting at least seven days (or any duration if hospitalization is needed). Manic episodes in Bipolar I are severe enough to cause marked impairment in social or occupational functioning and may include psychotic features (delusions of grandiosity, paranoid ideation, hallucinations). Most people with Bipolar I also experience major depressive episodes, but depression is not required for the diagnosis. Bipolar I carries the highest acute risk of hospitalization, harm to self or others, and treatment-emergent psychosis.

Bipolar II disorder

Bipolar II is defined by at least one hypomanic episode AND at least one major depressive episode in a lifetime, with no history of a full manic episode. Hypomania lasts at least four days, involves the same symptom cluster as mania but at lower severity, and does not cause severe functional impairment or psychotic features. Bipolar II is not a "milder" or "lesser" form of Bipolar I: depressive episodes are typically more frequent, longer, and more disabling than in Bipolar I, and suicide risk is comparable or higher. Because hypomania can feel like high energy, productivity, or improved mood — sometimes even welcomed — the diagnosis is often delayed by years while only the depression is treated.

Cyclothymic disorder

Cyclothymic disorder is defined by numerous periods of hypomanic symptoms and numerous periods of depressive symptoms present for at least two years in adults (one year in children and adolescents), with symptoms present at least half the time and no symptom-free period longer than two months. Crucially, neither the hypomanic nor the depressive symptoms ever meet full episode criteria — if they do, the diagnosis changes to Bipolar I, Bipolar II, or major depressive disorder. Cyclothymia is chronic and often disabling despite the milder individual episodes; without treatment, roughly 15–50% of cases progress to Bipolar I or Bipolar II over time.

Other specifiers and presentations

• Rapid cycling: Four or more mood episodes (mania, hypomania, or depression) within a 12-month period. More common in Bipolar II and in women; often associated with antidepressant exposure or thyroid dysfunction.
• Mixed features: A mood episode in which symptoms of the opposite pole are present at the same time (e.g., a depressive episode with racing thoughts, agitation, and decreased need for sleep). Mixed-features episodes carry elevated suicide risk and respond differently to medication.
• With psychotic features: Delusions or hallucinations during a mood episode, mood-congruent (themes of grandiosity in mania; themes of guilt or worthlessness in depression) or mood-incongruent.
• With seasonal pattern: Episodes consistently occurring at the same time of year (often winter depressions, summer hypomanias).
• Peripartum onset: A mood episode beginning during pregnancy or within four weeks of delivery. Postpartum mania and mixed states are obstetric emergencies; see postpartum depression for related considerations.

Symptoms of a Manic or Hypomanic Episode

A manic or hypomanic episode is a change from the person's baseline, lasting most of the day, nearly every day, for the required duration (≥7 days for mania, ≥4 days for hypomania, or any duration if hospitalization is needed). The DSM-5-TR criteria require both Criterion A (the mood/energy change) and three or more of the seven Criterion B symptoms — or four if the mood is only irritable.

The distinction between mania and hypomania is severity and duration, not symptom type:

• Mania lasts at least 7 days (or any duration if hospitalization is required), causes marked impairment in social or occupational functioning, may include psychotic features, and often requires inpatient care.
• Hypomania lasts at least 4 consecutive days, involves the same symptoms but is clearly observable as a change from baseline, does not cause severe impairment, does not include psychotic features, and does not require hospitalization. Hypomania can feel like an enjoyable burst of energy and creativity — which is one reason Bipolar II is so often missed for years.

In either case, the episode is a categorical change that is noticeable to people who know the person well: sleep collapses but energy soars, speech becomes pressured, plans multiply, judgment narrows, and consequences pile up.

Symptoms of a Bipolar Depressive Episode

The depressive episodes in bipolar disorder use the same DSM-5-TR criteria as major depressive disorder. A diagnosis requires five or more of the following symptoms, present for at least two weeks, with at least one being depressed mood or loss of interest/pleasure, and representing a change from previous functioning.

Bipolar depression often differs subtly from unipolar depression: hypersomnia and increased appetite ("atypical features") are more common, episodes may be shorter but more frequent, and antidepressant monotherapy can trigger mania or rapid cycling. These differences are why accurate diagnosis matters before treatment begins.

Causes and Risk Factors

Bipolar disorder is one of the most heritable psychiatric conditions, but no single gene, life event, or biological marker causes it. The current scientific consensus describes a multifactorial model: genetic vulnerability sets the baseline risk, neurobiological differences shape how mood is regulated, and environmental stressors trigger episodes in vulnerable individuals.

Genetic factors

• Heritability is estimated at 60–85% based on twin and family studies — among the highest in psychiatry, comparable to schizophrenia.
• First-degree relatives of someone with bipolar disorder have a roughly 10-fold increased risk of developing the condition (about 5–10% lifetime risk vs. ~1% in the general population).
• Concordance in identical twins is approximately 40–70%, confirming that genes account for the majority of variance but environmental factors matter.
• No single "bipolar gene" exists; the genetic architecture is polygenic, involving hundreds of common variants of small effect plus rare variants of larger effect. Genes implicated include those affecting calcium-channel signaling (CACNA1C), circadian regulation (CLOCK, BMAL1), and neuroplasticity (BDNF, ANK3).

Neurobiological factors

• Structural and functional brain differences: Neuroimaging shows reduced gray matter in the prefrontal cortex, abnormalities in the amygdala and hippocampus, and altered connectivity in mood-regulation networks. These differences are present from early in the illness and are not simply consequences of episodes.
• Neurotransmitter dysregulation: Bipolar disorder involves abnormalities in dopamine, serotonin, glutamate, and GABA signaling. The specific patterns differ between manic and depressive states, which is why no single medication treats both phases equally well.
• Mitochondrial and metabolic dysfunction: Emerging research implicates mitochondrial energy dysregulation and oxidative stress in bipolar pathophysiology, partially explaining medication response patterns (lithium, for instance, has mitochondrial protective effects).
• Circadian rhythm disruption: People with bipolar disorder often have unstable sleep-wake cycles, abnormal melatonin secretion, and increased sensitivity to circadian disruption. Sleep loss is one of the most reliable triggers for mania.

Environmental and psychosocial factors

• Stressful life events — bereavement, job loss, relationship breakdown, financial crisis — frequently precede first episodes and recurrences, particularly early in the illness.
• Childhood trauma and adversity roughly double the risk of developing bipolar disorder and are associated with earlier onset, more rapid cycling, more suicide attempts, and worse treatment response. See childhood trauma for more.
• Substance use — particularly stimulants (cocaine, amphetamines), cannabis, and alcohol — can trigger mania, accelerate cycling, and worsen the course. Bipolar disorder and addiction co-occur at high rates.
• Sleep disruption from shift work, jet lag, new parenthood, or insomnia can precipitate mood episodes; protecting sleep is a cornerstone of relapse prevention.
• Postpartum period: Childbirth carries the highest hormonal-event risk for first manic episodes in women with bipolar vulnerability.
• Seasonal factors: Light exposure changes can trigger depression (typically in winter) and hypomania or mania (typically in spring or summer) in some people.

Risk factor summary

The strongest predictors of bipolar disorder are: a first-degree relative with the condition, early-onset depression that does not respond well to antidepressants, postpartum psychosis or mania, childhood-onset mood instability, and history of antidepressant-induced manic or hypomanic switch.

Prevalence and Course

Bipolar disorder is a global condition with a relatively consistent prevalence across countries, suggesting strong biological underpinnings beyond cultural context.

• Lifetime prevalence in U.S. adults: ~4.4% across the bipolar spectrum (Bipolar I, II, and subthreshold conditions); ~2.8% in any given 12-month period.
• Bipolar I: ~1.0% lifetime prevalence; roughly equal in men and women.
• Bipolar II: ~1.1% lifetime prevalence; slightly more common in women, with higher rates of rapid cycling and depressive predominance.
• Cyclothymic disorder: ~0.4–1.0% lifetime prevalence; often underdiagnosed.
• Age of onset: Average around 25 years; ~75% of cases begin before age 35. Earlier onset (childhood, adolescence) is associated with stronger genetic loading and more chronic course.
• Sex distribution: Bipolar I affects men and women roughly equally. Bipolar II affects women more often, with higher rates of mixed features, rapid cycling, and seasonal patterns.

~25 years

Source: National Institute of Mental Health (NIMH)

Course over the lifespan

Bipolar disorder is chronic and recurrent. Without treatment, episodes tend to become more frequent and shorter cycles emerge — a phenomenon sometimes called "kindling." With treatment, the picture changes substantially:

• Time spent symptomatic: Untreated, people with bipolar disorder spend roughly 30–50% of their adult life symptomatic. With sustained treatment, this drops substantially.
• Episode recurrence: Roughly 70–90% of people with Bipolar I will have a recurrence within five years of an index episode without maintenance treatment; rates fall to ~30–40% with adherent medication and therapy.
• Functional recovery: Many people achieve symptomatic remission but lag in functional recovery (return to prior work, relationships, and self-care). Closing this gap is a central goal of psychosocial treatment.
• Suicide: Lifetime suicide risk in bipolar disorder is approximately 6–7% — one of the highest of any psychiatric condition. Risk is elevated during depressive and mixed-features episodes and in the early years after diagnosis. Sustained treatment (especially with lithium) substantially reduces this risk.
• Comorbidity: Roughly 50–70% of people with bipolar disorder have at least one co-occurring psychiatric condition over their lifetime.

Co-occurring Conditions

Bipolar disorder rarely appears alone. Comorbidities shape symptom presentation, complicate treatment, and require integrated rather than parallel care.

• Anxiety disorders: ~50–75% lifetime comorbidity. Generalized anxiety, panic disorder, and social anxiety are most common. Anxiety can mask hypomania and complicate medication choices.
• Substance use disorders: ~40–60% lifetime comorbidity, the highest among major psychiatric conditions. Substances often serve as self-medication and frequently trigger or prolong episodes.
• ADHD: ~10–20% comorbidity in adults; higher in those with childhood onset. ADHD and hypomania share symptoms (distractibility, talkativeness, impulsivity) but differ in episodic vs. continuous presentation.
• PTSD and trauma-related disorders: Higher than general-population rates, especially in those with childhood trauma histories.
• Borderline personality disorder: Real co-occurrence happens, but the conditions are also frequently confused. BPD involves reactive mood shifts in hours, triggered by interpersonal events; bipolar involves sustained episodes lasting days to weeks. Treatment differs substantially.
• Eating disorders: Particularly binge eating disorder and bulimia, often during depressive phases.
• Medical comorbidities: Cardiovascular disease, metabolic syndrome, diabetes, and thyroid disease all occur at higher rates and are partly driven by medication side effects (atypical antipsychotics, valproate) plus illness-related lifestyle factors. Routine medical monitoring is part of standard care.
• Self-harm and suicidal ideation: Lifetime rates are substantially elevated, particularly during depressive and mixed-features episodes.

Co-occurring substance use is the single most important factor that worsens bipolar treatment outcomes; addressing it (often in integrated care) is non-negotiable for sustained stability.

Diagnosis and Clinical Assessment

There is no blood test, brain scan, or biomarker that diagnoses bipolar disorder. Diagnosis is clinical, made by an experienced mental health professional through a structured interview combined with longitudinal history, collateral information from family or partners, and review of past treatment response. The single most consequential question is whether the person has ever had a manic or hypomanic episode — because the answer determines whether the diagnosis is bipolar disorder or unipolar depression, and therefore which treatments are safe and effective.

Why bipolar disorder is often missed

• Hypomania feels good. People rarely seek treatment during hypomania; they present in depression and report only the low periods.
• The first episode is often a depression. It can take 5–10 years on average from first depressive episode to accurate bipolar diagnosis, particularly for Bipolar II.
• Antidepressant trials hint at the diagnosis. Multiple failed antidepressant trials, antidepressant-induced agitation or insomnia, or "wired" responses to SSRIs are suggestive of underlying bipolarity.
• Collateral history matters. Family members or long-term partners often recall episodes of decreased sleep, accelerated activity, or impulsive decisions that the patient minimized or did not recognize.

Standardized assessment instruments

• Mood Disorder Questionnaire (MDQ): A 13-item self-report screen for lifetime manic or hypomanic symptoms. Useful in primary care and outpatient psychiatry as a first-pass screen.
• Bipolar Spectrum Diagnostic Scale (BSDS): A narrative self-report screen that captures softer bipolar-spectrum presentations.
• Hypomania Checklist (HCL-32): A 32-item screen for hypomanic symptoms, designed to catch the Bipolar II presentations missed by depression-only intake.
• Young Mania Rating Scale (YMRS): Clinician-administered scale for tracking manic symptom severity over time; standard in research and inpatient settings.
• Montgomery–Åsberg Depression Rating Scale (MADRS) or Hamilton Depression Rating Scale (HDRS): Used to track depression severity in bipolar treatment.
• Structured Clinical Interview for DSM-5 (SCID-5): The research-grade diagnostic interview; the most thorough confirmation of diagnosis.

What a thorough bipolar assessment includes

• Full DSM-5-TR criteria check for manic, hypomanic, and major depressive episodes, with attention to duration, severity, and functional impact
• Longitudinal mood history (a life chart, plotting episodes over time)
• Family psychiatric history across at least two generations
• Collateral history from a partner, parent, or close friend
• Substance use, sleep, and medical history (including thyroid function and any history of head injury, seizures, or steroid exposure)
• Suicide risk assessment using a structured tool
• Differential against major depressive disorder, borderline personality disorder, ADHD, substance-induced mood disorders, and medical causes (thyroid dysfunction, neurological conditions)
• Review of prior medication trials with specific attention to antidepressant response and any history of switching
• Current functional status across work, relationships, and self-care

Evidence-Based Medication Treatment

Medication is foundational to bipolar treatment. Unlike many psychiatric conditions where therapy alone produces robust outcomes, bipolar disorder requires pharmacotherapy as the primary treatment, with psychotherapy as the essential complement. Medications target three phases: acute mania, acute bipolar depression, and maintenance (relapse prevention). No single medication treats all three phases optimally.

The four main medication classes

Lithium — the gold standard

Lithium is the most evidence-based mood stabilizer and the only medication with a robust signal for suicide prevention in bipolar disorder (a reduction of suicide risk of roughly 60–80% in long-term treatment). It is first-line for maintenance treatment of Bipolar I, particularly effective in classic euphoric mania and in people with strong family histories. The drawbacks are real: narrow therapeutic window (overdose risk), need for regular blood-level monitoring, and side effects that some patients find intolerable (tremor, cognitive dulling, thirst). For many people, the benefits substantially outweigh the burdens — lithium remains the most carefully studied and most reliably effective medication for bipolar disorder over decades of use.

Valproate (divalproex)

Valproate is fast-acting in acute mania and useful in mixed-features episodes and rapid cycling, where it often outperforms lithium. It is absolutely contraindicated in pregnancy and in women of childbearing potential without robust contraception, due to a high risk of neural tube defects and neurodevelopmental harm to the fetus. Weight gain, sedation, and metabolic side effects are common.

Lamotrigine

Lamotrigine is first-line for bipolar depression and depression-predominant maintenance, particularly in Bipolar II. It has minimal anti-manic effect, so it is not used as monotherapy in acute mania. The most important safety concern is the small risk of Stevens-Johnson syndrome — a potentially fatal skin reaction that is largely preventable by a slow titration schedule over 6–8 weeks.

Atypical antipsychotics

Several atypical antipsychotics have FDA approval for bipolar disorder: olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, asenapine, cariprazine, and lurasidone. They are first-line for acute mania (especially with psychotic features), and several (quetiapine, lurasidone, cariprazine) are approved for bipolar depression. They have rapid onset compared to lithium and valproate, do not require blood-level monitoring, and can be used in pregnancy with risk-benefit discussion. The trade-offs are metabolic side effects (weight gain, dyslipidemia, glucose intolerance) and, with long-term use, risk of tardive dyskinesia. Modern atypicals like aripiprazole, lurasidone, and cariprazine have more favorable metabolic profiles than older agents like olanzapine.

Antidepressants in bipolar disorder

The use of antidepressants in bipolar disorder is clinically contested. Current expert consensus (CANMAT/ISBD guidelines, APA practice guideline):

• Antidepressants are not first-line for bipolar depression in most cases. First-line options include quetiapine, lurasidone, cariprazine, lamotrigine, or lithium.
• Antidepressants should never be used as monotherapy in Bipolar I (high risk of manic switch) and should be used with caution and only with a mood stabilizer in Bipolar II.
• SSRIs and bupropion carry lower switch risk than tricyclics or SNRIs and are preferred when antidepressants are used.
• Discontinue antidepressants if a manic or hypomanic switch, mixed features, or rapid cycling emerges.

Other medications and treatments

• Carbamazepine and oxcarbazepine are second-line mood stabilizers, useful in mixed episodes and in patients intolerant to lithium or valproate.
• Benzodiazepines are used short-term for acute agitation, insomnia, or anxiety during episodes — not as long-term mood stabilizers.
• Thyroid hormone (T3 or T4 augmentation) can help in treatment-resistant bipolar depression.
• Electroconvulsive therapy (ECT) remains highly effective for severe, treatment-resistant, or catatonic mania and for severe bipolar depression with high suicide risk. It is often underused due to stigma despite excellent safety and efficacy data.
• Transcranial magnetic stimulation (TMS) and ketamine/esketamine are emerging options for treatment-resistant bipolar depression, with growing but still preliminary evidence.

Combination treatment

In practice, most people with Bipolar I are managed on two-drug combinations — typically a mood stabilizer (lithium or valproate) plus an atypical antipsychotic, with additional medications added for specific symptoms or phases. The principle is to target the specific clinical problem (mania, depression, mixed features, rapid cycling) with the medication best suited for it, while minimizing polypharmacy where possible.

Evidence-Based Psychotherapy

Psychotherapy is not optional in bipolar disorder treatment — it is the second pillar of standard care alongside medication. Adjunctive psychotherapy reduces relapse rates, shortens episodes, improves medication adherence, and substantially improves functional outcomes (work, relationships, self-care) that medication alone does not fully address. Five approaches have the strongest evidence base.

Cognitive Behavioral Therapy (CBT) for Bipolar Disorder

Cognitive Behavioral Therapy (CBT) adapted for bipolar disorder helps people identify early warning signs of mood episodes, challenge cognitive distortions that intensify mood states (catastrophizing in depression, grandiosity in hypomania), build behavioral activation skills for depression, and develop relapse-prevention plans. CBT for bipolar typically runs 20–25 sessions and produces meaningful reductions in depressive symptoms and relapse rates when added to medication. See CBT for bipolar disorder for more.

Interpersonal and Social Rhythm Therapy (IPSRT)

IPSRT, developed by Ellen Frank and colleagues, is specifically designed for bipolar disorder. It combines interpersonal psychotherapy (IPT) — which addresses grief, role transitions, interpersonal disputes, and interpersonal deficits — with social rhythm therapy, which stabilizes daily routines (sleep, wake, meals, activity, social contact) on the principle that circadian and social-rhythm disruption is a key trigger for episodes. IPSRT has strong evidence for reducing recurrence in Bipolar I, particularly in the maintenance phase, and is unique among bipolar therapies in directly targeting biological rhythm vulnerability.

Family-Focused Therapy (FFT)

Family-focused therapy (FFT), developed by David Miklowitz, is delivered in 21 sessions over nine months and involves the person with bipolar disorder together with family members (typically parents, partners, or adult children). It has three components: psychoeducation about the illness, communication enhancement training, and problem-solving skills training. FFT has strong evidence for reducing relapse, shortening episodes, and improving family functioning, particularly in adolescents and young adults living with family. Because expressed emotion (high criticism, hostility, or emotional over-involvement in the home) is a robust predictor of relapse, restructuring family communication produces measurable clinical benefit.

Psychoeducation

Structured psychoeducation programs — often delivered in 6–12 weekly group sessions — teach people with bipolar disorder and their families about the condition, medication, early warning signs, relapse prevention, and lifestyle factors. The landmark Barcelona Psychoeducation trial (Colom et al.) demonstrated that 21 weekly group psychoeducation sessions reduced relapse rates substantially over five years compared to standard care. Psychoeducation is often the first psychosocial intervention offered after diagnosis and is the foundation that other therapies build on.

Dialectical Behavior Therapy (DBT) Skills

Although Dialectical Behavior Therapy (DBT) was developed for borderline personality disorder, its skills modules — mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness — have growing evidence for bipolar disorder, particularly for managing inter-episode mood instability, impulsivity during hypomania, and emotional reactivity during recovery. DBT skills groups are increasingly offered as adjuncts to medication management. See DBT for bipolar disorder for more.

Comparing the main psychotherapies

Other supportive approaches

• Group therapy for bipolar disorder offers peer support, normalization, and shared problem-solving alongside structured psychoeducation. See group therapy.
• Mindfulness-Based Cognitive Therapy (MBCT) has emerging evidence for reducing depressive relapse in bipolar disorder, particularly in the maintenance phase.
• Couples therapy focused on bipolar disorder (often integrating FFT principles) helps partners understand the illness, recognize early warning signs, and rebuild communication patterns disrupted during episodes. See bipolar disorder and relationships.
• Peer support and lived-experience programs (DBSA — Depression and Bipolar Support Alliance — meetings, peer specialists) are increasingly integrated into care.

Lifestyle and Self-Management

Sustained bipolar stability is not achieved by medication alone or therapy alone — it depends on a set of daily habits that support the biological systems most disrupted by the illness.

• Sleep regularity: Consistent sleep and wake times are arguably the single most important behavioral lever. Sleep loss is a reliable mania trigger; oversleeping can deepen depression. Most people benefit from a strict sleep window protected by sleep hygiene and sometimes melatonin.
• Substance avoidance: Alcohol, stimulants, cannabis, and recreational drugs reliably destabilize mood and interact with medications. This is non-negotiable for sustained stability.
• Mood tracking: Daily or weekly mood charts (paper, apps like eMoods or Daylio) help detect early warning signs before episodes crystallize.
• Stress and routine management: Predictable daily routines, regular meals, regular activity, and limits on shift work and travel reduce circadian stress.
• Exercise: Regular moderate exercise has antidepressant effects and supports sleep, but excessive exercise during hypomania can fuel the episode.
• Light exposure: Morning light exposure stabilizes circadian rhythm in depression; light avoidance in the evening (and sometimes a dark therapy or eye masks in mania) can help in episodes.
• Early warning recognition: Most people, with practice, learn personal "warning signs" — decreased sleep, increased talkativeness, irritability, racing thoughts on the manic side; withdrawal, fatigue, loss of interest on the depressive side. Knowing these signs allows preemptive action.
• Family and partner education: Loved ones who understand the illness can support early intervention and reduce the relational damage of episodes.
• Crisis planning: A written plan (signs that warrant a doctor call, signs that warrant ER, key contacts, medication adjustments to discuss with the prescriber) is standard practice and dramatically improves response time when episodes emerge.

See living with bipolar disorder daily management for a deeper guide.

Bipolar Disorder in Adolescents and Young Adults

Bipolar disorder frequently emerges in adolescence or early adulthood, and recognizing it early substantially improves long-term outcomes. Pediatric bipolar disorder is a recognized but contested diagnosis — DSM-5-TR criteria apply, but adolescent presentations can include more irritability than euphoria, more mixed-features episodes, and significant comorbidity with ADHD and anxiety. Family-focused therapy, psychoeducation, and careful medication selection (with attention to growth, metabolic effects, and reproductive considerations) are central. See teen bipolar treatment for parent-focused guidance.

Prognosis — Realistic and Hopeful

The historical view of bipolar disorder as a uniformly disabling illness is incomplete. The honest picture, drawn from long-term studies (the Stanley Foundation Bipolar Network, the Jorvi Bipolar Study, the McLean-Harvard First-Episode Project):

• Most people achieve symptomatic stability with adherent treatment — typically combination medication plus psychotherapy and lifestyle support.
• Functional recovery lags symptomatic recovery. Many people return to "well enough" before they return to prior work performance, relationship quality, or independence. Psychosocial treatment narrows this gap.
• Recurrence is the rule, not the exception. Even with adherent treatment, most people experience future episodes. The goal is to make episodes fewer, shorter, less severe, and less disruptive — not to eliminate them entirely.
• Outcomes are dramatically better than they were a generation ago. Modern combination treatment, structured psychotherapy, and earlier diagnosis have substantially improved both symptomatic and functional outcomes.
• Suicide risk, while elevated, is reducible. Lithium, sustained psychotherapy, restricted access to means during high-risk periods, and consistent care all reduce risk significantly.
• Many people with bipolar disorder have stable careers, partnerships, families, and meaningful lives. The diagnosis is serious — it is not a sentence.

The honest message is: bipolar disorder is a lifelong condition, treatment is a long-term commitment, episodes are likely to recur — and with the right combination of medication, therapy, lifestyle structure, and supportive relationships, most people achieve stability and many lead fully functional lives.

When to Seek Help

Consider reaching out to a mental health professional, psychiatrist, or primary care doctor if you:

• Have experienced periods of decreased need for sleep with elevated energy, racing thoughts, and pressured speech that lasted several days
• Have had episodes of depression that did not respond well to antidepressants, or that became agitated, "wired," or worse on antidepressants
• Notice mood shifts that last days to weeks (not hours), often with changes in sleep, energy, and behavior
• Have a family history of bipolar disorder, schizophrenia, or recurrent severe mood disorders
• Have made impulsive decisions during high-energy periods (spending sprees, risky sex, abrupt life changes) that you later regretted
• Have thoughts of suicide or self-harm — see suicidal ideation and self-harm for more
• Are a partner, parent, or close friend of someone whose mood and behavior cycle in ways that disrupt their life
• Recently gave birth and are experiencing rapid mood changes, severe sleep loss without fatigue, or psychotic symptoms — postpartum mania is an obstetric emergency
• Have been diagnosed with depression or anxiety but feel the picture doesn't fully fit

You do not need to be in a full manic or depressive episode to deserve evaluation. Early diagnosis substantially improves long-term outcomes.

To begin care, find a therapist with experience in mood disorders, or talk to your primary care doctor about a psychiatric referral. For guidance on the structure of mental health care, see levels of care.

Frequently Asked Questions

Bipolar disorder is treatable — combination care works

Medication plus evidence-based psychotherapy plus lifestyle structure produces sustained stability for most people. A clinician with mood-disorder experience can help you build the right plan.

Find a therapist